While NMNAT2 levels may decrease with age (potentially increasing vulnerability), recent clinical trials suggest NAM, another NAD+ precursor, is safe and effective for glaucoma, a neurodegenerative disease [135,136]. The gene discussed is NMNAT2; the disease is neurodegenerative disease.